Placebo 10 mg

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC, University of Oxford

Conditions

ApathyEffort Based Decision MakingProsocial BehaviorType 2 Diabetes Mellitus

Phase 1

Effort and Antidepressant Study Test

Not yet recruitingNCT06696482

University of OxfordApathy, Effort Based Decision Making, Prosocial Behavior

Start: 2025-01-31End: 2025-09-30Target: 50Updated: 2024-11-20

Phase 3

A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

CompletedNCT01986855

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2013-12-02End: 2016-09-28Updated: 2018-09-10

Related Papers

Ertugliflozin + metformin as a treatment option for type 2 diabetes

Expert Opinion on Pharmacotherapy2021-06-164 citations

Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials

Diabetes Therapy2020-07-0914 citations

Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials.

2020-05-0518 citations

Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus

Current Medical Research and Opinion2020-04-2310 citations

Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus

Current Medical Research and Opinion2020-04-233 citations

Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.

2020-01-039 citations

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study.

2017-11-20111 citations